Related Experiment Video
Updated: Oct 3, 2025
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
In vivo experimental mouse model to test CD19CAR T cells generated with different methods
Anne Fåne1, Marit Renée Myhre1, Else Marit Inderberg1
1Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Abstract:
Pre-clinical evaluation of CAR T cells includes procedures testing T-cell efficacy and safety in as close to real world conditions as possible. An important step in efficacy testing is the in vivo study, most often using immunodeficient murine models into which both the poison and the cure are injected; namely a human cancer cell line and genetically modified human T cells. The capacity of the T cells to control the cancer progression will provide information about the CAR T-cell efficacy. We here provide a protocol to test CAR T cells in vivo using the validated anti-B-cell marker CD19CAR and an aggressive lymphoma model.
Insights
This study details a protocol for testing chimeric antigen receptor (CAR) T-cells in vivo. The method uses a CD19CAR T-cell therapy and a lymphoma model to assess CAR T-cell efficacy against cancer progression.
Area of Science:
- Immunotherapy
- Oncology
- Pre-clinical Research
Background:
- Pre-clinical evaluation of CAR T-cells is crucial for assessing therapeutic potential.
- In vivo studies using murine models are standard for testing CAR T-cell efficacy and safety.
- Evaluating CAR T-cell capacity to control cancer progression provides key efficacy data.
Purpose of the Study:
- To provide a detailed protocol for in vivo testing of CAR T-cells.
- To establish a method for assessing the efficacy of CD19CAR T-cells.
- To utilize an aggressive lymphoma model for robust pre-clinical evaluation.
Main Methods:
- Development of a protocol for in vivo CAR T-cell efficacy testing.
- Utilizing immunodeficient murine models for pre-clinical studies.
- Employing human cancer cell lines and genetically modified human T-cells in vivo.
- Using a validated anti-B-cell marker, CD19CAR, for targeted therapy.
Main Results:
- The protocol allows for the assessment of CAR T-cell control over cancer progression in vivo.
- Demonstrates the application of CD19CAR T-cells in an aggressive lymphoma model.
- Provides a framework for evaluating the efficacy of CAR T-cell therapies.
Conclusions:
- The presented protocol offers a standardized approach for in vivo CAR T-cell efficacy testing.
- This method is valuable for advancing the pre-clinical evaluation of immunotherapies.
- The study validates the use of CD19CAR T-cells in a relevant aggressive lymphoma model.
